Compare HSBC Holdings plc (HSBC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Sanofi SA — how do they compare? HSBC Holdings plc trades at $104 (market cap $353.82B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: HSBC Holdings plc is far larger — about 3.4× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| HSBC | SNY | |
|---|---|---|
Market Cap | $353.82B | $104.30B |
Sector | Technology | Health |
52-Week High | $107.86 | $52.34 |
52-Week Low | $63.84 | $41.33 |
Dividend Yield | 3.63% | 5.55% |
Enterprise Value | — | $124.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $104.12, up 0.77% today, with a bullish technical signal from moving averages and support near $103. The bank reported strong Q2 2026 results with a 7% revenue increase and a $1 billion buyback, while net income margin improved to 34.54% in 2026. Analyst sentiment is mixed, with 38.1% buy ratings, but recent news includes a Citi downgrade citing a 40% stock run-up.
The outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory changes and valuation concerns after the recent rally. Further upside depends on sustained revenue growth and effective capital allocation.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
